Hepatitis B Treatment Market Size

Hepatitis B Treatment Market Overview

The hepatitis b treatment market is expected to reach USD 129.40 Billion by 2032 at 4.5% CAGR during the forecast period 2023-2032.

The viral infection is caused by Hepatitis A, B or C virus which causes liver infection leading to liver damage. Hepatitis B virus can transmit in contact with infected blood, by consumption of contaminated water, and by using infected needles. Some of the major symptoms are weakness, jaundice, poor appetite, dark-coloured urine, skin itching, leg swelling, weight loss, drowsiness and others. The rise in concern for a better treatment for Hepatitis B is boosting the market at the global level.

The availability of hepatitis B treatment and the awareness of hepatitis B infections will significantly drive the market in the forecast period. The concern and reasonable treatment are the two growth factors that highly accelerate the market’s growth. The advancement in the development of new treatments and medications with a higher success rate will lead the market towards greater opportunities. The continuous development of drugs and vaccines for hepatitis B treatment is aiding the market. AIDS survivors with haemodialysis and immunosuppressants are propelling the market’s growth in the forecast period

Hepatitis B Treatment Market Segmentation

The hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.

Based on type, the market is segmented into acute and chronic. On the basis of treatment, the hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery  (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.

Based on region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Hepatitis B Treatment Market Key players

Some of the key players in the hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others.

Hepatitis B Treatment Regional Market Summary

Global Hepatitis B Treatment Market Share (%), by Region, 2017

Sources: Centers for Disease Control and Prevention, GOV.UK, Society of Cardiovascular Computed Tomography, Indian Brand Equity Foundation, Annual Reports, Press Release, White Paper, And Company Presentation

The Americas dominates the global market for hepatitis B treatment owing to the increasing bacterial infection, development in the clinical practices, and availability and access of best treatments for viral infection in this region.

Moreover, high healthcare expenditure within the Americas boosts the regional market. According to the National Vaccine Information Center, there were 3,370 acute cases of hepatitis B in the US in 2015. Following similar trends, Europe stood second in the global hepatitis B treatment market. On a regional basis, the European market is segmented into Western Europe and Eastern Europe. Europe is estimated to lead the market due to the presence of advanced medical facilities and rising viral infection among the population contributes to increasing the new cases of hepatitis B among the population. According to the World Health Organization data sheet, hepatitis B and C affects a large number of people in the European region. It also, stats that globally, 1.5 million people die every year because of hepatitis B virus. The increasing incidences of hepatitis B in Europe boost market growth.

Asia Pacific is estimated to be the fastest growing region for the hepatitis B treatment market in 2017. A rapidly growing medical diagnostic sector, growing prevalence of bacterial infection and a large number of patients suffering from HIV infection support market growth.

On the other hand, the Middle East and Africa hold the least share in the hepatitis B treatment market owing to stringent government policies, presence of poor economies, lack of awareness, and low healthcare expenditure within the region. Hepatitis B Treatment Market, by Type

• Acute


• Chronic

Hepatitis B Treatment Market, by Treatment

• Immune Modulator Drugs
  
  
  
  • Pegylated Interferon
  
  
  • Interferon Alpha
  
  
  
  

• Antiviral Drugs
  
  
  
  • Tenofovir disoproxil
  
  
  • Entecavir
  
  
  • Telbivudine
  
  
  • Lamivudine
  
  
  • Others
  
  
  
  

• Vaccine


• Surgery (Liver Transplant)

Hepatitis B Treatment Market, by Distribution Channel

• Hospital & Retail Pharmacies


• Online Pharmacies

Hepatitis B Treatment Market, by Key Players

• Accord Healthcare Inc.


• Apotex Corp.


• Arbutus Biopharma


• Arrowhead Pharma


• Aurobindo Pharma Limited


• Bristol-Myers Squibb Company


• Gilead Sciences, Inc.


• GlaxoSmithKline


• Lupin Pharmaceuticals, Inc.


• Merck & Co., Inc.


• Par Pharmaceutical, Inc.


• Teva Pharmaceuticals


• Zydus Pharmaceuticals

Recent Development

In April 2022

Gilead Sciences, Inc. has declared that U.S. Food and Drug Administration (FDA) approved its new drug application (sNDA) for Veklury (remdesivir) for pediatric patients treatment older than 28 days, weighing 3 kg. Patients with COVID-19 or moderate COVID-19 are considered at high risk for progression hospitalization or death. This approval for sNDA follows Veklury non-hospitalized adult and adolescent patients treated at high risk of severe COVID-19.

In April 2022

Antios Therapeutics, Inc, a global clinical-stage biopharmaceutical company that has developed advanced therapies for the treatment of chronic hepatitis B virus. It has recently been announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application Phosphoramidates for Hepatitis B Virus treatment. The compositions contain Antios' novel Active Site Polymerase Inhibitor Nucleotide), ATI-2173, along with other therapies and mechanisms.

Intended Audience

• Pharmaceutical Companies


• Biotechnological Institutes


• Government and Private Laboratories


• Research and Development (R&D) companies


• Medical Research Laboratories

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report